B-ring modified aurones as promising allosteric inhibitors of hepatitis C virus RNA-dependent RNA polymerase. 2014

Amel Meguellati, and Abdelhakim Ahmed-Belkacem, and Wei Yi, and Romain Haudecoeur, and Marie Crouillère, and Rozenn Brillet, and Jean-Michel Pawlotsky, and Ahcène Boumendjel, and Marine Peuchmaur
Univ. Grenoble Alpes, DPM UMR 5063, 38041 Grenoble, France; CNRS, DPM UMR 5063, 38041 Grenoble, France.

Following our recent report showing the potential of naturally occurring aurones (2-benzylidenebenzofuran-3(2H)-ones) as anti-hepatitis C virus (HCV) agents, efforts were continued in order to refine the structural requirements for the inhibitory effect on HCV RNA-dependent RNA polymerase (RdRp). In this study, we targeted the B-ring moiety of aurones with the aim to improve structural features associated with higher inhibition of the targeted polymerase. In vitro evaluation of the RdRp inhibitory activity of the 37 newly synthesized compounds pointed out that the replacement of the B-ring with an N-substituted indole moiety induced the highest inhibitory effect. Of these, compounds 31, 40 and 41 were found to be the most active (IC50 = 2.3-2.4 μM). Docking experiments performed with the most active compounds revealed that the allosteric thumb pocket I of RdRp is the binding pocket for aurone analogues.

UI MeSH Term Description Entries
D008958 Models, Molecular Models used experimentally or theoretically to study molecular shape, electronic properties, or interactions; includes analogous molecules, computer-generated graphics, and mechanical structures. Molecular Models,Model, Molecular,Molecular Model
D011487 Protein Conformation The characteristic 3-dimensional shape of a protein, including the secondary, supersecondary (motifs), tertiary (domains) and quaternary structure of the peptide chain. PROTEIN STRUCTURE, QUATERNARY describes the conformation assumed by multimeric proteins (aggregates of more than one polypeptide chain). Conformation, Protein,Conformations, Protein,Protein Conformations
D004791 Enzyme Inhibitors Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. Enzyme Inhibitor,Inhibitor, Enzyme,Inhibitors, Enzyme
D000494 Allosteric Regulation The modification of the reactivity of ENZYMES by the binding of effectors to sites (ALLOSTERIC SITES) on the enzymes other than the substrate BINDING SITES. Regulation, Allosteric,Allosteric Regulations,Regulations, Allosteric
D000998 Antiviral Agents Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. Antiviral,Antiviral Agent,Antiviral Drug,Antivirals,Antiviral Drugs,Agent, Antiviral,Agents, Antiviral,Drug, Antiviral,Drugs, Antiviral
D001572 Benzofurans Compounds that contain a BENZENE ring fused to a furan ring. Coumarones,Diphenylbenzofuran
D012324 RNA-Dependent RNA Polymerase An enzyme that catalyses RNA-template-directed extension of the 3'- end of an RNA strand by one nucleotide at a time, and can initiate a chain de novo. (Enzyme Nomenclature, 1992, p293) Nucleoside-Triphosphate:RNA Nucleotidyltransferase (RNA-directed),RNA Replicase,RNA-Dependent RNA Replicase,RNA-Directed RNA Polymerase,RNA Dependent RNA Polymerase,RNA Dependent RNA Replicase,RNA Directed RNA Polymerase,RNA Polymerase, RNA-Dependent,RNA Polymerase, RNA-Directed,RNA Replicase, RNA-Dependent,Replicase, RNA,Replicase, RNA-Dependent RNA
D016174 Hepacivirus A genus of FLAVIVIRIDAE causing parenterally-transmitted HEPATITIS C which is associated with transfusions and drug abuse. Hepatitis C virus is the type species. Hepatitis C virus,Hepatitis C-Like Viruses,Hepaciviruses,Hepatitis C Like Viruses,Hepatitis C viruses,Hepatitis C-Like Virus

Related Publications

Amel Meguellati, and Abdelhakim Ahmed-Belkacem, and Wei Yi, and Romain Haudecoeur, and Marie Crouillère, and Rozenn Brillet, and Jean-Michel Pawlotsky, and Ahcène Boumendjel, and Marine Peuchmaur
August 2011, Journal of medicinal chemistry,
Amel Meguellati, and Abdelhakim Ahmed-Belkacem, and Wei Yi, and Romain Haudecoeur, and Marie Crouillère, and Rozenn Brillet, and Jean-Michel Pawlotsky, and Ahcène Boumendjel, and Marine Peuchmaur
January 2010, Current medicinal chemistry,
Amel Meguellati, and Abdelhakim Ahmed-Belkacem, and Wei Yi, and Romain Haudecoeur, and Marie Crouillère, and Rozenn Brillet, and Jean-Michel Pawlotsky, and Ahcène Boumendjel, and Marine Peuchmaur
March 2006, Infectious disorders drug targets,
Amel Meguellati, and Abdelhakim Ahmed-Belkacem, and Wei Yi, and Romain Haudecoeur, and Marie Crouillère, and Rozenn Brillet, and Jean-Michel Pawlotsky, and Ahcène Boumendjel, and Marine Peuchmaur
October 2010, Viruses,
Amel Meguellati, and Abdelhakim Ahmed-Belkacem, and Wei Yi, and Romain Haudecoeur, and Marie Crouillère, and Rozenn Brillet, and Jean-Michel Pawlotsky, and Ahcène Boumendjel, and Marine Peuchmaur
August 2003, Antimicrobial agents and chemotherapy,
Amel Meguellati, and Abdelhakim Ahmed-Belkacem, and Wei Yi, and Romain Haudecoeur, and Marie Crouillère, and Rozenn Brillet, and Jean-Michel Pawlotsky, and Ahcène Boumendjel, and Marine Peuchmaur
August 2006, Bioorganic & medicinal chemistry letters,
Amel Meguellati, and Abdelhakim Ahmed-Belkacem, and Wei Yi, and Romain Haudecoeur, and Marie Crouillère, and Rozenn Brillet, and Jean-Michel Pawlotsky, and Ahcène Boumendjel, and Marine Peuchmaur
July 2004, Biochemistry. Biokhimiia,
Amel Meguellati, and Abdelhakim Ahmed-Belkacem, and Wei Yi, and Romain Haudecoeur, and Marie Crouillère, and Rozenn Brillet, and Jean-Michel Pawlotsky, and Ahcène Boumendjel, and Marine Peuchmaur
January 2000, Current topics in microbiology and immunology,
Amel Meguellati, and Abdelhakim Ahmed-Belkacem, and Wei Yi, and Romain Haudecoeur, and Marie Crouillère, and Rozenn Brillet, and Jean-Michel Pawlotsky, and Ahcène Boumendjel, and Marine Peuchmaur
January 1999, Methods in molecular medicine,
Amel Meguellati, and Abdelhakim Ahmed-Belkacem, and Wei Yi, and Romain Haudecoeur, and Marie Crouillère, and Rozenn Brillet, and Jean-Michel Pawlotsky, and Ahcène Boumendjel, and Marine Peuchmaur
January 1996, Methods in enzymology,
Copied contents to your clipboard!